Dorsal Raphe Serotonergic Neurons In Parkinson'S Disease is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The dorsal raphe nucleus provides the majority of serotonergic innervation to the forebrain and is affected in Parkinson's disease, contributing to non-motor symptoms. [1]
| Property | Value | [2]
|----------|-------| [3]
| Cell Type | Serotonergic Projection Neurons | [4]
| Location | Dorsal Raphe Nucleus (Midbrain) |
| Neurotransmitters | Serotonin (5-HT) |
| Associated Diseases | Parkinson's Disease, Depression |
| Model Systems | Mouse models, iPSC-derived neurons |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000850 | serotonergic neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000850 | serotonergic neuron | Exact |
The dorsal raphe nucleus (DRN) is the primary source of serotonergic innervation to the forebrain. The serotonin (5-HT) biosynthesis pathway involves:
Alpha-synuclein (SNCA) pathology affects dorsal raphe serotonergic neurons in PD:
Serotonergic neurons in the DRN are particularly vulnerable to mitochondrial dysfunction:
Microglial activation in the DRN contributes to serotonergic neuron loss:
Serotonergic denervation in PD contributes to:
The study of Dorsal Raphe Serotonergic Neurons In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Paulus & K., Serotonergic dysfunction in PD (1993). 1993. ↩︎
Politis & Niccolini, Serotonin in PD depression (2015). 2015. ↩︎
Huot et al. Serotonin in non-motor symptoms of PD (2010). 2010. ↩︎
Qin et al. Dorsal raphe degeneration in PD (2022). 2022. ↩︎
Walther et al. TPH2: The rate-limiting enzyme for serotonin synthesis (2003). 2003. ↩︎
Christensen et al. AADC and neurotransmitter synthesis (2008). 2008. ↩︎
Eiden & Weihe, VMAT2 and neurotransmitter transport (2011). 2011. ↩︎
Dauer & Przedborski, PINK1 and PARKIN in PD (2003). 2003. ↩︎
Schapira et al. Non-motor symptoms in PD (2017). 2017. ↩︎
Krystal et al. TPH2 gene therapy approaches (2020). 2020. ↩︎